Mostrar el registro sencillo del ítem
| dc.contributor.author | Soler-Espejo, Eva | |
| dc.contributor.author | Chen, Yang | |
| dc.contributor.author | Rivera-Caravaca, José-Miguel | |
| dc.contributor.author | Ramos-Bratos, María-Pilar | |
| dc.contributor.author | López-Gálvez, Raquel | |
| dc.contributor.author | Marín, Francisco | |
| dc.contributor.author | Roldán-Schilling, Vanessa | |
| dc.contributor.author | Lip, Gregory-Y-H | |
| dc.date.accessioned | 2026-03-06T14:24:25Z | |
| dc.date.available | 2026-03-06T14:24:25Z | |
| dc.date.issued | 2025-07-10 | |
| dc.identifier.citation | Soler-Espejo E, Chen Y, Rivera-Caravaca JM, Ramos-Bratos MP, López-Gálvez R, Marín F, et al. Remnant-to-LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF project III (MAFP-III) cohort study. Cardiovasc Diabetol. 10 de julio de 2025;24(1):275. doi:10.1186/s12933-025-02831-4 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/24865 | |
| dc.description.abstract | BACKGROUND: Remnant cholesterol (RC) has emerged as an independent contributor to residual cardiovascular risk, beyond low-density lipoprotein cholesterol (LDL-C). As atrial fibrillation (AF) is a common arrhythmia associated with increased thromboembolic risk even despite anticoagulation, we assessed the prognostic value of RC in AF, with a particular focus on its association with LDL-C discordance. METHODS: In this prospective cohort study, AF outpatients initiating oral anticoagulation between January 2016 and November 2021 were enrolled. Baseline LDL-C and RC levels were measured, and patients were stratified into four groups based on these values. The primary outcome was a composite of thromboembolic events; secondary outcomes included major adverse cardiovascular events (MACE), cardiovascular death, and all-cause death. Associations between RC levels and clinical outcomes across LDL-C strata were assessed using multivariable Cox proportional hazards models and as a continuous variable using restricted cubic spline (RCS) analyses. RESULTS: Among 1,694 patients (52.5% female; median age 76 years (IQR 69-82); mean follow-up: 1.86 years, SD 0.4 years), 5.7% (97) experienced incident thromboembolic events. In the low LDL-C group, RCS analysis showed a significant linear association between RC levels and thromboembolic risk (p-overall = 0.044). High RC levels were independently associated with an increased risk of thromboembolic events compared to the low RC subgroup (aHR 1.82; 95% CI, 1.03-3.23; p = 0.039), but this was nonsignificant in the high LDL-C group. For secondary outcomes, higher RC levels were not significantly associated with increased adverse event risk in either LDL-C group. CONCLUSION: Despite low LDL-C levels in AF patients, elevated RC levels were still independently associated with a higher thromboembolic risk, suggesting discordance between RC and LDL-C in risk stratification among patients with AF. | |
| dc.language.iso | eng | |
| dc.publisher | BMC | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internacional | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Atrial Fibrillation/drug therapy/diagnosis/mortality/blood/epidemiology | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Thromboembolism/diagnosis/mortality/prevention & control/epidemiology/blood | |
| dc.subject.mesh | Prospective Studies | |
| dc.subject.mesh | Risk Assessment | |
| dc.subject.mesh | Biomarkers/blood | |
| dc.subject.mesh | Cholesterol, LDL/blood | |
| dc.subject.mesh | Anticoagulants/adverse effects/administration & dosage | |
| dc.subject.mesh | Time Factors | |
| dc.subject.mesh | Aged, 80 and over | |
| dc.subject.mesh | Risk Factors | |
| dc.subject.mesh | Treatment Outcome | |
| dc.subject.mesh | Predictive Value of Tests | |
| dc.subject.mesh | Incidence | |
| dc.subject.mesh | Dyslipidemias/blood/diagnosis/mortality | |
| dc.subject.mesh | Administration, Oral | |
| dc.title | Remnant-to-LDL cholesterol discordance as a predictor of thromboembolic events in anticoagulated patients with atrial fibrillation: a report from the prospective Murcia AF project III (MAFP-III) cohort study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 40640836 | |
| dc.relation.publisherversion | https://cardiab.biomedcentral.com/articles/10.1186/s12933-025-02831-4 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1186/s12933-025-02831-4 | |
| dc.journal.title | Cardiovascular Diabetology | |
| dc.identifier.essn | 1475-2840 |